The Lancet

Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced?

With an increasing number of available drugs along with a focus on early treatment regimens and drug sequencing in Crohn's disease, data from prospective, well designed studies to guide on drug choice ...
Le Lézard

LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound

Eli Lilly and Company and Walmart Inc. today announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect.

Carrier Reports Third Quarter 2025 Results

Carrier Global Corporation (NYSE:CARR), global leader in intelligent climate and energy solutions, today reported financial results for the third quarter of 2025.

10 Best CEFs This Month: Average Yield Of 9% Plus (October 2025)

For income investors, closed-end funds remain an attractive investment class that covers various asset classes. Check out ...

Atomera Incorporated (ATOM) Q3 2025 Earnings Call Transcript

Q3 2025 Earnings Call October 28, 2025 5:00 PM EDTCompany ParticipantsMike BishopScott Bibaud - President, CEO ...
Le Lézard

U.S. FDA Approves Updated Indication for WINREVAIRtm (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Pha…

Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label based on the Phase 3 ZENITH ...

U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on ...

WINREVAIR is the subject of a licensing agreement with Bristol Myers Squibb.